Clinical trial
A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs…
NCT00468897 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00468897 |
|---|---|
| Title | A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites. |
| Official title | An Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of a Tablet Formulation of Rosiglitazone XR (BRL-049653) 8mg Manufactured at Two Different Sites in Healthy Volunteers in Fasting Conditions |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | RSG XR |
| Enrollment | 50 |
| Start date | Mar 21, 2007 |
| Primary completion | May 2, 2007 |
| Completion | May 2, 2007 |
| First posted | May 3, 2007 |
| Last update posted | Aug 7, 2017 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: